No Data
No Data
Lipocine Inc. Reports 2024 Financial Turnaround
Lipocine Announces Initiation Of A Phase 3 Trial For LPCN 1154 Which Is In Development For Treatment Of Postpartum Depression
Express News | Lipocine Inc: Patient Dosing Expected in Q2/2025
Express News | Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of Lpcn 1154
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Cuts Target Price to $6.75